GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » Cyclically Adjusted PS Ratio

Vicore Pharma Holding AB (STU:6Y4) Cyclically Adjusted PS Ratio : 24.73 (As of Jun. 01, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB Cyclically Adjusted PS Ratio?

As of today (2025-06-01), Vicore Pharma Holding AB's current share price is €0.742. Vicore Pharma Holding AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €0.03. Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio for today is 24.73.

The historical rank and industry rank for Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:6Y4' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 22.57   Med: 29.2   Max: 34.04
Current: 29.5

During the past years, Vicore Pharma Holding AB's highest Cyclically Adjusted PS Ratio was 34.04. The lowest was 22.57. And the median was 29.20.

STU:6Y4's Cyclically Adjusted PS Ratio is ranked worse than
87.9% of 496 companies
in the Biotechnology industry
Industry Median: 5.345 vs STU:6Y4: 29.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vicore Pharma Holding AB's adjusted revenue per share data for the three months ended in Mar. 2025 was €0.000. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.03 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vicore Pharma Holding AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Cyclically Adjusted PS Ratio Chart

Vicore Pharma Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 30.05

Vicore Pharma Holding AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 30.05 25.27

Competitive Comparison of Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio falls into.


;
;

Vicore Pharma Holding AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.742/0.03
=24.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Vicore Pharma Holding AB's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0/132.8245*132.8245
=0.000

Current CPI (Mar. 2025) = 132.8245.

Vicore Pharma Holding AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.001 99.995 0.001
201509 0.002 100.228 0.003
201512 0.002 100.276 0.003
201603 0.001 100.751 0.001
201606 0.002 101.019 0.003
201609 0.001 101.138 0.001
201612 0.002 102.022 0.003
201703 0.001 102.022 0.001
201706 0.001 102.752 0.001
201709 0.002 103.279 0.003
201712 0.001 103.793 0.001
201803 0.000 103.962 0.000
201806 0.001 104.875 0.001
201809 0.001 105.679 0.001
201812 0.000 105.912 0.000
201903 0.000 105.886 0.000
201906 0.000 106.742 0.000
201909 0.000 107.214 0.000
201912 0.000 107.766 0.000
202003 0.000 106.563 0.000
202006 0.000 107.498 0.000
202009 0.000 107.635 0.000
202012 0.000 108.296 0.000
202103 0.000 108.360 0.000
202106 0.000 108.928 0.000
202109 0.000 110.338 0.000
202112 0.000 112.486 0.000
202203 0.000 114.825 0.000
202206 0.000 118.384 0.000
202209 0.000 122.296 0.000
202212 0.000 126.365 0.000
202303 0.000 127.042 0.000
202306 0.000 129.407 0.000
202309 0.000 130.224 0.000
202312 0.000 131.912 0.000
202403 0.082 132.205 0.082
202406 0.000 132.716 0.000
202409 0.000 132.304 0.000
202412 0.002 132.987 0.002
202503 0.000 132.825 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vicore Pharma Holding AB  (STU:6Y4) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vicore Pharma Holding AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines